Namur Thrombosis and Hemostasis Center

INIS

1. patients 100%
2. anticoagulants 77%
3. thrombin 53%
4. reviews 51%
5. risks 51%
6. plasma 47%
7. laboratories 42%
8. comparative evaluations 38%
9. concentration 36%
10. proteins 34%
11. drugs 33%
12. assessments 32%
13. evaluation 31%
14. data 31%
15. testing 28%
16. heparin 25%
17. levels 25%
18. diseases 22%
19. thrombosis 21%
20. doses 20%
21. blood 20%
22. antibodies 20%
23. control 20%
24. values 19%
25. inhibition 19%
26. sensitivity 19%
27. performance 18%
28. safety 18%
29. screening 17%
30. biological markers 17%
31. administration 17%
32. applications 17%
33. monitoring 17%
34. in vitro 17%
35. tyrosine 16%
36. nanoparticles 16%
37. kinases 16%
38. humans 16%
39. women 16%
40. covid-19 15%
41. reagents 15%
42. estrogens 15%
43. neutrophils 14%
44. vaccines 14%
45. receptors 14%
46. cancer 14%
47. information 13%
48. rats 13%
49. validation 13%
50. synthesis 13%
51. therapy 12%
52. in vivo 12%
53. inflammation 12%
54. standardization 12%
55. molecular weight 12%
56. vitamin k 11%
57. detection 11%
58. design 11%
59. emergencies 11%
60. myeloid leukemia 10%
61. tissues 10%
62. toxicity 10%
63. production 10%
64. coronaviruses 10%
65. hemostatics 9%
66. range 9%
67. recommendations 9%
68. management 9%
69. surgery 9%
70. interactions 9%
71. mass spectrometry 8%
72. venoms 8%
73. thromboplastin 8%
74. symptoms 7%
75. prothrombin 7%
76. endothelium 7%
77. accuracy 7%
78. adhesion 7%
79. clinical trials 6%
80. molecules 6%
81. populations 6%
82. blood coagulation 6%
83. lungs 6%
84. dimers 6%
85. surveys 6%
86. capacity 6%
87. reduction 6%
88. medicines 6%
89. kidneys 6%
90. hormones 6%
91. peaks 6%
92. economics 6%
93. investigations 6%
94. liver 5%
95. wave forms 5%
96. fibrinolysis 5%
97. hemolysis 5%
98. substrates 5%
99. ligands 5%
100. mortality 5%